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1.1. General features of monogenic diseases 
 
Monogenic diseases result from modifications in a single gene occurring in all cells 
of the body. Though they are relatively rare, they can affect millions of patients 
worldwide. Scientists currently estimate that over 10,000 of human diseases are 
known to be monogenic. Pure genetic diseases are caused by a single error in a 
single gene in the human DNA. The nature of the disease depends on the functions 
of the modified gene. The single-gene or monogenic diseases can basically be 
inherited in three different manners: dominant, recessive and X-linked.  
Dominant diseases are monogenic disorders that involve damage to only one gene 
copy, recessive diseases are monogenic disorders that occur due to damages in both 
copies, while X-linked diseases are monogenic disorders that are linked to defective 
genes on the X chromosome. The X-linked alleles can also be dominant or 
recessive. These alleles are expressed equally in men and women, more so in men 
as they carry only one copy of X chromosome (XY) whereas women carry two 
(XX).  
The global prevalence of all single gene diseases at birth is approximately 10/1000 
(Orphanet Database, www.orpha.net). Monogenic diseases affect nationwide only 
a few patients, but altogether they affect a significant portion of the populations 
since their thousands of different types are known. In general, these disorders are 
less known than the common, multifactorial ones. They occur rarely in the everyday 
practice of the medical practitioners and less attention is paid for the research of 
these diseases (Kelsall et al., 2013).  
Monogenic diseases can vary greatly in their severity. They can cause mild, severe 
or very severe symptoms and can be associated with phenotypic diversity like 
common diseases. Their symptoms can significantly impair the life quality of the 
patient and they can also result in stigmatization and difficulties in socialization 







1.2. Clinical management of monogenic diseases – the importance of genetic 
counseling 
 
Genetic counseling gives the patient information about how genetic conditions 
might affect the patient or his/her family. The genetic counselor or other healthcare 
professional will collect the patient’s personal and family health history. They can 
use this information to determine how likely it is that the patient or his/her family 
member has a genetic condition. Based on this information, the genetic counselor 
can help the patient decide whether a genetic test might be right for the patient or 
his/her relative.  
Based on your personal and family health history, your doctor can refer you for 
genetic counseling. There are different stages in your life when you might be 
referred for genetic counseling.  
Before the patient becomes pregnant genetic counseling can address concerns about 
monogenic diseases that might affect the baby of the patient during infancy or 
childhood or the ability of the patient to become pregnant.  
Genetic counseling is important while the patient is pregnant, it can address certain 
tests that may be done during the pregnancy to detect monogenic diseases that might 
affect the baby of the patient during infancy or childhood.  
Genetic counseling can address concerns if a child is showing signs and symptoms 
of a monogenic disease. 
Genetic counseling can be helpful if the patient has symptoms of a monogenic 
disease or has a family history of a monogenic condition that makes him or her 
more likely to be affected with that condition.  
Following the genetic counseling session, the patient might decide to have genetic 
testing. Genetic counseling after testing can help the patient better understands the 
test results and treatment options, help the patient deal with emotional concerns, 
and refer the patient to other healthcare providers and advocacy and support groups. 
 
1.3. Recent milestones in the background of knowledge explosion in the 
understanding of monogenic diseases 
 
As a result of the Human Genome Project (HGP) and the development of next-





monogenic diseases. In the last 30 years, many disease causing genes and mutations 
have been identified and the genetic background of many monogenic diseases have 
been elucidated (Figure 1.). As an example we demonstrate the timeline of the 
discoveries of the genetic background of Charcot-Marie-Tooth (CMT) disease. 
However, it can occur that sequencing is unable to answer clinically relevant 
questions regarding phenotypic diversity and/or disease prognosis (Jarinova et al., 
2012; Timmerman et al., 2014; Kiritsi et al., 2015; Smith et al., 2019). 
 
 
Figure 1. Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame 
of the HGP Success. The number of the annually, newly identified causative 
genes show two peaks: one is explained by the HGP, the other is the consequence 
of the fast development of sequencing, next-generation sequencing technologies 
(Timmerman et al., 2014). 
 
1.4. The investigated monogenic diseases 
 
In my thesis, I have summarized the results of my genetic investigations in 
monogenic diseases: the clinical variants of the cylindromatosis gene (CYLD) 
mutation-caused disease spectrum such as multiple familial trichoepithelioma type 
1 (MFT1), familial cylindromatosis (FC) and Brooke-Spiegler syndrome (BSS) and 
the clinical variants of the cathepsin C (CTSC) mutation-caused disease spectrum 
such as the Papillon-Lefèvre syndrome (PLS) and the Haim-Munk syndrome 
(HMS). My investigations focused on the identification of putative phenotype 
modifying genetic factors in these rare monogenic diseases, which are responsible 
for the observed phenotypic differences among the affected patients carrying the 






1.4.1. Clinical variants of the CYLD mutation-caused spectrum 
 
Brooke-Spiegler syndrome (BSS) is a rare monogenic skin disease characterized by 
the development of skin appendage tumors such as cylindromas, trichoepitheliomas 
and spiradenomas (Evans 1954; Bignell et al., 2000). The first symptoms of BSS 
are small skin-colored papules, which occur in childhood and adolescence (Evans, 
1954). These tumors grow slowly in size and continue to appear throughout the 
lifetime of the patient (Nagy et al., 2015). Expression of the papules exhibits wide 
variation among and within affected families (Bignell et al., 2000).  
 
 
Figure 2. The severity and diversity of the symptoms of the clinical variants 
of the CYLD mutation-caused spectrum. In general, missense mutations of the 
CYLD gene is associated with the mildest symptoms and in approximately 50% of 
the cases they results in the development of MFT1. Nonsense mutations of the 
CYLD gene are associated with the most severe symptoms and with the highest 
diversity of the symptoms of the affected patients, they can lead to the 
development of FC, MFT1 and BSS with approximately equal frequency.  
(Nagy et al., 2015). 
 
BSS is transmitted as an autosomal dominant condition affecting males and females 
equally (Guggenheim and Schnyder, 1961). BSS and its phenotypic variants were 





2000; Biggs et al., 1995; Takahashi et al., 2000). Within the mapped region, the 
cylindromatosis gene (CYLD) was identified as the causative gene responsible for 
the development of the disease (Bignell et al., 2000). The CYLD gene (GenBank 
accession number NM_015247) spans 56 kb and contains 20 exons, the first 3 of 
which are untranslated, and 19 introns. Of the 17 known splice variants, 13 affect 
protein coding regions, and the remaining produce non-coding transcripts 
(http://ensemble.org). The tumor suppressor CYLD gene encodes an enzyme with 
deubiquitinase activity. The CYLD enzyme posttranslationally modifies its target 
proteins by removing Lys63-linked ubiquitin chains (Kovalenko et al., 2003). The 
protein interacts with several members of the NF-kB signaling pathway, including 
the TRAF2, TRAF6, NEMO and BCL3 proteins, acting as a negative regulator 
(Hutti et al., 2009). 
 
 
Figure 3. The Hungarian BSS pedigree of Bukovinian (Romania) origin. The 
clinical pictures of the severe hairy scalp symptoms of the affected individuals are 
represented from the (a) 2nd, (b) 3rd, (c and d) 4th and (e) 5th generations. (f) The 









Concerning the so far reported phenotypes and the associated CYLD mutations, it 
is difficult to establish genotype-phenotype correlations in BSS. However, the 
elucidation of the genotype-phenotype correlations has significant clinical 
relevance in promoting the understanding of disease mechanism and contributing 
to the development of future therapeutic modalities. The picture is even more 
complex, since mutations of the CYLD gene have been identified in patients with 
phenotypic features of either BSS, FC or MTF1 suggesting that these syndromes 
are clinical variants of the CYLD mutation-caused spectrum (Figure 2., Rajan et al., 




Figure 4. The investigated Anglo-Saxon pedigree from the North of England. 
Clinical pictures of the affected individuals from the 4th generation show tumors 
(a) above the ear, (b) on the forehead, and (c) around the nose. (d) The pedigree 
contains 8 affected family members spanning 5 generations (Nagy et al., 2013). 
 
A Hungarian pedigree from Bukovina (Romania) affected by BSS (Figure 3.) and 





study. The clinical phenotypes of the affected family members and the pedigrees 
are reported in detail in a previous paper from our research group (Nagy et al., 
2013). The patients of the Hungarian BSS pedigree were presented with severe 
symptoms: numerous large tumors arising from different skin appendages and 
developing on the scalp, face and trunk mainly (Nagy et al., 2013). The patients of 
the Anglo-Saxon pedigree showed moderate severity: few tumors, small size arising 
from different skin appendages developing primarily on the face (Figure 4., Nagy 
et al., 2013). 
Out of the previously reported patients, two Hungarian and two Anglo-Saxon ones, 
affected by the different phenotypes of BSS, but carrying the same disease-causing 
mutation (c.2806C>T, p.Arg936X) in the CYLD gene (Nagy et al., 2013) were 
enrolled to the study. 
 
1.4.2. Clinical variants of the CTSC mutation-caused spectrum 
 
Papillon-Lefèvre syndrome (PLS) and Haim-Munk syndrome (HMS) are 
characterized by overlapping dermatological and dental symptoms, including 
hyperkeratosis of the palms and soles as well as severe periodontitis (Selvaraju et 
al., 2003; Nagy et al., 2014). Patients with PLS can also develop mild mental 
retardation, calcification of the dura mater, hyperhidrosis and increased 
susceptibility to infections (Gorlin et al., 1964; Haneke et al., 1979; Dalgic et al., 
2011). Specific features of HMS include pes planus, arachnodactyly, acroosteolysis 
and onychogryphosis (Papillon et al., 1924; Haim et al., 1965; Hart et al., 1999).  
The prevalence of PLS is approximately four cases per million, and, to date, 
approximately 300 cases have been reported worldwide. Parental consanguinity has 
been noted in more than 50% of these cases (Hewitt et al., 2004). The prevalence 
of HMS is approximately one case per million, and the majority of reported cases 
are descendants of a few consanguineous families from a religious isolate in 
Cochin, India. One unrelated Brazilian patient has also been reported. Fewer than 
100 HMS cases have been reported in the literature to date (Papillon et al., 1924; 
Haim et al., 1965; Hart et al., 1999). 
The ratio of affected males to females is 1:1 for both syndromes. PLS and HMS are 
both inherited in an autosomal recessive manner and develop as a consequence of 





So far 89 CTSC gene mutations have been identified (Sulák et al., 2016). The 
majority of these mutations have been detected in PLS patients, whereas only 4% 
have been associated with HMS (Selvaraju et al., 2003; Nagy et al., 2014). 
In light of the reported PLS and HMS phenotypes and the associated CTSC 
mutations, it was hypothesized that PLS and HMS are the same entity with different 
phenotypic appearances (Table I., Sulák et al., 2016). Although it is difficult to 
establish genotype–phenotype correlations, the elucidation of these correlations is 
likely to have significant clinical relevance for the development of the different 
clinical variants (PLS and HMS), the disease mechanism and the development of 
future therapeutic modalities. 
 
 
Table I. Comparison of the symptoms of the clinical variants of the CTSC 
mutation-caused spectrum. 
 
The clinical phenotypes of the affected patients were reported in detail in a previous 
paper from our research group (Sulák et al., 2016). A Hungarian woman presented 
with a typical HMS phenotype (Figure 5.): mild hyperkeratotic plaques were 
observed symmetrically on her palms and soles, onychogryphosis and 
arachnodactyly were noted on her fingers and pes planus on her soles. 
A Hungarian male patient presented with the classical PLS phenotype (Figure 5.): 
moderate hyperkeratosis on his palms and soles. Both patients were missing all 
permanent teeth and using a permanent dental prosthesis. In our previous paper, we 





siblings (Sulák et al., 2016). It was not possible to genotype unaffected relatives 
(Sulák et al., 2016).  
 
 
Figure 5. The clinical symptoms of the HMS and PLS Patients. HMS Patient 
exhibited (a) mild hyperkeratosis on her palms, (b) onychogryphosis and 
arachnodactly of her fingers and mild hyperkeratosis and (c) pes planus on her 
soles. PLS Patient was affected by moderate hyperkeratosis of his (d) palms and 
(f) soles, and exhibited no specific symptoms of HMS. (e) No other affected 
individuals are known in the family of the PLS Patient, and HMS Patient was 
brought up in state care without knowing her relatives (Sulák et al., 2016). 
 
The two previously reported Hungarian patients affected by PLS and HMS carrying 
the same disease-causing mutation (c.748C/T; p.Arg250X) of the CTSC gene were 
investigated (Sulák et al., 2016) in the current study. 
  
PLS Patient 










2.1. Aims related to the CYLD-mutation caused clinical variants 
 
In order to comprehensively profile coding variants and identify putative 
phenotype-modifying genetic factors - which could potentially explain the observed 
clinical differences between the Hungarian and the Anglo-Saxon BSS pedigrees 
carrying the same causative CYLD mutation - we performed whole exome 
sequencing (WES). 
Here we report an investigation of Hungarian and Anglo-Saxon BSS pedigrees, 
which have been chosen as they both carry the same recurrent germline mutation in 
the CYLD gene (c.2806C>T, p.Arg936X), yet they show striking difference in their 
phenotypes (Nagy et al., 2013). These two pedigrees provide an excellent 
opportunity to identify phenotype-modifying genetic factors that are responsible for 
the phenotypic diversity in BSS.  
 
2.2. Aims related to the CTSC-mutation caused clinical variants 
 
In order to identify putative phenotype-modifying genetic factors - which could 
explain the observed clinical differences between the PLS and HMS patients 
carrying the same causative CTSC mutation – WES was performed. 
We have recently investigated two Hungarian patients, one with the symptoms of 
PLS and one with the symptoms of HMS, who nonetheless carry the same 
homozygous nonsense mutation (c.748C/T; p.Arg250X) of the CTSC gene (Sulák 
et al., 2016). As there is currently no explanation for why one mutation can lead to 
these two different clinical variants (PLS and HMS), we became interested in the 
identification of phenotype-modifying genetic factors that could facilitate the 










The clinical details of the investigated patients are demonstrated in the introduction 
part of the thesis. Their clinical features have been reported in the previous 




3.2.1. DNA samples 
 
Out of the previously reported patients, two Hungarian and two Anglo-Saxon ones, 
affected by the different phenotypes of BSS, but carrying the same disease-causing 
mutation (c.2806C>T, p.Arg936X) in the CYLD gene, were investigated (Nagy et 
al., 2013). DNA samples from the patients (n=4) were used for WES (performed 
by UD-GenoMed Medical Genomic Technologies Ltd., Debrecen, Hungary; 
http://www.ud-genomed.hu/).  
Two previously reported Hungarian patients affected by PLS and HMS carrying the 
same disease-causing mutation (c.748C/T; p.Arg250X) of the CTSC gene were 
investigated (Sulák et al., 2016). DNA samples from both patients were subjected 
to WES, which was performed by UD-GenoMed Medical Genomic Technologies 
Ltd.  
The quality of the DNA samples was evaluated by agarose-gel electrophoresis.  
 
3.2.2. Whole exome sequencing (WES) 
 
Briefly, 4 µg of DNA with a concentration of 100 ng/µL were used for library 
construction. A liquid chip capture system (Agilent Research Laboratories, Santa 
Clara, CA, USA) was used to efficiently enrich all human exon regions. High-
throughput deep sequencing was subsequently performed on the Illumina (San 
Diego, CA, USA) platform. An exon kit (SureSelect Human All Exon V6 Kit; 
Agilent) was used for library construction and capture experiments, and a 





insert size. The Illumina platform was used for sequencing according to the 
effective concentration of the library and the data output requirements. High-
throughput paired-end sequencing (paired-end 150 bp; PE150) was performed.  
 
3.2.3. Bioinformatics analysis 
 
After WES was completed, bioinformatics analysis was performed, including 
quality assessment of sequencing data, single-nucleotide polymorphism (SNP) 
detection and whole exome association analysis.  
The sequencing data quality control requirements were as follows: sequencing error 
rate of each base position < 1%, mean Q20 ratio > 90%, mean Q30 ratio > 80%, 
mean error rate < 0.1%, alignment rate for sequencing reads ≤ 95% and read depth 
of the base at one position ≥ 10X.  
 
3.2.4. Single nucleotide polymorphism (SNP) testing 
 
SNP testing was performed as follows: high-quality sequences were aligned with 
the human reference genome (GRCh37/hg19) to detect sequence variants, and the 
detected variations were analyzed and annotated. Variants were filtered according 
to read depth, allele frequency, and prevalence in genomic variant databases such 
as ExAc (v.0.3), ClinVar and Kaviar.  
Variant prioritization tools (PolyPhen2, SIFT, LRT, Mutation Taster, Mutation 
Assessor) were used to predict the functional impact of the variants. All the 
identified candidate variants were confirmed by direct sequencing (Delta Bio 2000 







4. RESULTS  
 
4.1. Identification of three putative genetic variants responsible for phenotypic 
variants in BSS 
 
Gene SNP  Polyphen2 SIFT MutationTaster 
ABCA13 rs74790141 Damaging Deleterious Disease causing 
ARID1B rs113232635 Unknown Tolerated Normal 
DECR1 rs550991042 Unknown Tolerated Disease causing 
EPB41L4A rs17266567 Damaging Deleterious Disease causing 
FGFR2 rs765066758 Benign Tolerated Disease causing 
HLA-A rs1136741 Damaging Tolerated Normal 









KALRN rs78202770 Damaging Deleterious Disease causing 





Damaging Deleterious Disease causing 




Deleterious Disease causing 
POM121L2 rs61736098 Damaging Deleterious Normal 
SMO rs111694017 Benign Tolerated Damaging 




Deleterious Disease causing 





Table II. WES identified 20 variants, which were all present in the 






A comparison of the WES data from the Hungarian and Anglo-Saxon BSS patients 
carrying the same disease-causing mutation (c.2806C>T, p.Arg936X) in the CYLD 
gene identified 20 genetic variants (Table II.), which were all present in the 
Hungarian patients, but not in the Anglo-Saxon patients. Based on the results of 
variant prioritization tools and the data of the literature, three of the 20 variants 
were suggested as putative phenotype-modifying polymorphisms. According to our 
current knowledge the other 17 variants are not associated with the functions of the 
CYLD enzyme.  
The three putative phenotype-modifying polymorphisms are the followings: the 
rs1053023 SNP of the signal transducer and activator of transcription 3 (STAT3) 
gene, the rs1131877 SNP of the tumor necrosis factor receptor-associated factor 3 
(TRAF3) gene and the rs202122812 SNP of the neighbor of BRCA1 gene 1 (NBR1) 
gene. The rs1053023 polymorphism is located in the 3’UTR region of the STAT3 
gene, while the other two polymorphisms (rs1131877 and rs202122812) are 
common missense variants of the TRAF3 and NBR1 genes, respectively. 
Pathogenicity predictions of the identified phenotype-modifying factors are 
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4.2. Identification of two putative genetic variants responsible for phenotypic 
variants in HMS and PLS 
 
A comparison of the WES data from the PLS and HMS patients carrying the same 
disease-causing mutation (c.748C/T; p.Arg250X) of the CTSC gene identified 35 
putative genetic variants (Table IV.), which were present in the HMS patient, but 
not in the PLS one. The PLS patient did not carry any extra polymorphisms 
compared to the HMS patient.  
 
Gene SNP Polyphen2 SIFT MutationTaster 








HLA- A rs9260156 Unknown Unknown Disease causing 
HLA- B rs1050683 Benign Tolerated Normal 
HLA- DQB1 rs41552812 Benign Tolerated Normal 
HLA- DQB1 rs1071637 Damaging Deleterious Normal 
HLA- DRB1 rs9269744 
Probably 
damaging 
Deleterious Disease causing 
HLA- DRB1 rs3830125 Benign Deleterious Unknown 
HLA- DRB1 rs1136881 
Probably 
damaging 
Deleterious Disease causing 
HLA- DRB1 rs1071752 Benign Deleterious Disease causing 




HLA- DRB1 rs148093782 Benign Deleterious Normal 
HLA- DRB5 rs41553512 
Probably 
damaging 
Tolerated Disease causing 
HLA- DRB5 rs41559420 Benign Tolerated Disease causing 
HLA- DRB5 rs1064587 Benign Deleterious Normal 
HLA- DRB5 rs701884 Benign Deleterious Disease causing 
HLA-DOA rs2582 Benign Unknown Disease causing 
HLA-DPB1 rs1042121 Benign Tolerated Disease causing 
HLA-DQA1 rs12722039 Benign Tolerated Disease causing 





HLA-DQA1 rs35087390 Benign Deleterious Disease causing 
HLA-DQB2 rs9276570 Benign Tolerated Disease causing 
HLA-DQB2 rs9276572 Damaging Deleterious Disease causing 
HLA-DRA1 rs7192 Benign Tolerated Unknown 
KIR2DL1 rs199644153 Benign Tolerated Normal 
KIR2DL1 rs200746024 Benign Tolerated Normal 
KIR2DL1 r538559888 Benign Tolerated Normal 
KIR2DL2 rs3810343 Benign Tolerated Normal 
KIR2DL2 rs35719984 Benign Tolerated Normal 
KIR2DL2 rs78713511 Benign Tolerated Normal 
KIR2DL2 rs200686594 Benign Tolerated Normal 
KIR2DL3 rs662386 Benign Deleterious Normal 





SH2D4A rs34608771 Benign Tolerated Polymorphism 
Table IV. WES identified 36 variants, which were all present in the HMS 
patient, but not in the PLS patient. 
 
Based on the results of variant prioritization tools and the data of the literature, two 
out of the 35 variants are suggested as putative phenotype-modifying 
polymorphisms. According to our current knowledge the other 33 variants are not 





















of the HMS 
phenotype 












of the HMS 
phenotype 
Pap et al.,  
2020 
Table V. Pathogenicity predictions and clinical associations of the identified 






The two putative phenotype-modifying polymorphisms are the followings: the 
rs34608771 SNP of the SH2 domain containing 4A (SH2D4A) gene and the 
rs55695858 SNP of the odorant binding protein 2A (OBP2A) gene. Both variants 
are common missense polymorphisms. Pathogenicity predictions for the identified 








Although the identification of disease-causing mutations is still extremely 
important for family planning and therapy, direct sequencing is unable to answer 
clinically relevant questions regarding phenotypic diversity and disease prognosis 
(Jarinova et al., 2012; Timmerman et al., 2014; Kiritsi et al., 2015; Smith et al., 
2019). This limitation of direct sequencing was encountered with the Hungarian 
and Anglo-Saxon BSS pedigrees previously reported by our workgroup (Nagy et 
al., 2013). Using haplotype analysis we have demonstrated that the presence of the 
same CYLD mutation in these geographically distant BSS families (the Hungarian 
one and the Anglo-Saxon one) is the consequence of two independent mutational 
events (Nagy et al., 2013). These results suggest the position of this recurrent 
mutation is a mutational hot spot on the CYLD gene (Nagy et al., 2013). 
Comparing the WES data of the Hungarian and Anglo-Saxon BSS patients, we 
identified three putative phenotype-modifying genetic variants that potentially 
explain the striking phenotypic differences among patients carrying the same 
disease-causing CYLD mutation. The genes harbouring these genetic modifying 
variants code for proteins that are either directly or undirectly functionally linked 
to CYLD (Figure 6.) 
 




STAT3 is a transcription factor, which is constitutively activated in a variety of 
human cancers and plays critical roles in cancer cell survival, metastasis and 





directly activates certain microRNAs (miRs), such as miR-21 and miR-181b-1 
(Aggarwal et al., 2009). MiR-21 and miR-181b-1 inhibit the enzymatic activity of 
CYLD, leading to increased nuclear factor‐κB (NF-κB) activity. Thus, STAT3 is 
not only a downstream target of IL-6 but, with miR-21, miR-181b-1 and CYLD, is 
part of the positive feedback loop that underlies the epigenetic switch that links 
inflammation to cancer (Iliopoulos et al., 2010). The B-cell CLL/lymphoma 3 
(BCL3) protein, which directly interacts with the STAT3 protein, is deubiquitinated 
by the CYLD enzyme, and abnormal BCL3 ubiquitination has been associated with 
the development of basal cell carcinomas (Chaudhary et al., 2015). It has been 
recently reported that BCL3 serves as an oncogene in cervical cancer and its 
oncogenic effect is mediated by STAT3 (Zhao et al., 2016). Interestingly, the 
rs1053023 SNP of the STAT3 gene has already been associated with multiple 
sclerosis (Lu et al., 2005) and reported in B-cell non-Hodgkin lymphoma 
(Butterbach et al., 2011). However, this is the first study that suggests a potential 
phenotype-modifying role for STAT3 in BSS. 
TRAF3 is a member of the TRAF family of proteins, which serve as both crucial 
intracellular adaptors and E3 ubiquitin ligases that mediate signaling after the 
activation of various receptors. Receptors that signal through TRAF proteins 
include those involved in inflammation, innate immune responses, cell death and, 
most notably, interact with the followings: tumor necrosis factor receptors, Toll‐
like receptors, RIG‐1‐like receptors and interleukin‐1 receptors (Wang et al., 2010; 
Hacker et al., 2011). The TRAF-interacting protein (TRAIP) interacts with TRAF3, 
while TRAIP is reported to interact with CYLD (Chapard et al., 2012). TRAIP 
expression is increased in basal cell carcinomas and in multiple breast epithelial cell 
lines with oncogenic potentials ranging from non-malignant to highly invasive 
(Almeida et al., 2011). Mutations in TRAF3 and CYLD leading to constitutive 
activation of NF‐κB have been identified in cancers, including multiple myeloma 
and solid tumors (Harhaj et al., 2012). The rs1131877 SNP of the TRAF3 gene is 
highly predictive for the development grade ≥2 acute esophageal postradiotherapy 
toxicity (De Ruyck et al., 2011), and here we have demonstrated its association with 
the phenotypic diversity in BSS.  
NBR1 is an autophagic adaptor protein involved in the efficient clearance of 
damaged mitochondria (Shi et al., 2015). Briefly, upon mitochondrial damage, E3 





they target damaged mitochondrial proteins for ubiquitination and bulk degradation 
by autophagy (Shi et al., 2014). NBR1 is a functional homolog of sequestosome 1 
(SQSTM1), another autophagic adaptor protein, which is a selective autophagy 
substrate that also acts as a cargo receptor for the degradation of other substrates 
(Svenning et al., 2011). The interaction of CYLD with TRAFs is dependent upon 
SQSTM1, and the absence of SQSTM1 results in the reduction of the activity of the 
CYLD enzyme (Wooten et al., 2008; Into et al., 2010).  The rs202122812 SNP of 
the NBR1 gene has not been previously associated with any human diseases: this is 
the first study to indicate its clinical relevance in the development of the BSS-
related phenotypic diversity. 
 
The comparison of the WES data of the HMS and PLS patients identified a putative 
phenotype-modifying genetic variant (rs34608771 SNP) in the SH2D4A gene, 
which encodes a T-cell-expressed adapter protein that is expressed in T-cells, B-
cells, macrophages and dendritic cells (Hashimoto et al., 2000). SH2D4A regulates 
T-cell receptor (TCR) signal transduction in T-cells, and, in human T-cells, its 
expression increased in response to T-cell activation (Gonçalves et al., 2018). 
SH2D4A is linked to cathepsin C via cystatin F. This latter protein is a cysteine-
protease inhibitor expressed selectively in immune cells, such as T-cells, NK cells 
and dendritic cells (Obata-Onai et al., 2002). The rs34608771 polymorphism of the 
SH2D4A gene has not been associated previously with any human diseases: this is 
the first study which links it to the development of the HMS clinical variant and 
raises its putative association with the phenotypic differences between PLS and 
HMS patients. 
The other putative phenotype-modifying genetic variant (rs55695858 SNP) is 
located within the OBP2A gene, which encodes an odorant-binding carrier protein 
that has a known environmental biosensor function (Lacazette et al., 2000). The 
OBP2A protein is expressed in the nasal structures, salivary and lachrymal glands 
and lungs, and, thus, has an oral sphere profile (Lapinski et al., 2009 and 2019). 
OBP2A interacts with the glycosyltransferase 6 domain containing 1 (GLT6D1) 
protein, encoded by the GLT6D1 gene, which has been identified as a susceptibility 
locus for periodontitis by genome-wide association studies and this association has 
been confirmed by several previous studies (Li et al., 2009; Hasim et al., 2015). 





the substrate-binding specificity of the encoded protein, none have previously been 
associated with the development of a human disease (Halfon et al., 1998; Hamilton 
et al., 2008). Since periodontitis is a major feature of the PLS and HMS phenotypes, 
we suggest that the rs55695858 SNP of the OBP2A gene might contribute to the 
phenotypic differences observed between PLS and HMS patients (Figure 7.).  
 
Figure 7. Schematic of the proposed mechanisms of the identified phenotype-
modifying factors. 
 
Further functional experiments are currently performed by our research group to 







Our study aimed to explain the phenotypic differences in BSS patients carrying the 
same disease-causing CYLD mutation by identifying phenotype-modifying genetic 
polymorphisms (Figure 8.) and to elucidate the phenotypic differences in PLS and 
HMS patients carrying the same disease-causing CTSC mutation by identifying 




Figure 8. The identified putative phenotype-modifying genetic variants can 
explain the differences in the severity of the clinical symptoms between BSS 
patients from Szekszárd and England carrying the same disease-causing CYLD 
mutation (p.Arg936X). 
 
It should be noted that, in addition to genetic factors, environmental or lifestyle 
factors might also contribute to the observed phenotypic differences between the 
investigated patients. Further functional studies are needed to prove the clinical 
relevance of the identified phenotype-modifying genetic factors and to describe the 
underlying mechanism that explain their phenotype-modifying roles. Our study 
contributes to the accumulating evidence supporting the clinical importance of 
phenotype-modifying genetic factors and their potential to facilitate the elucidation 
of genotype–phenotype correlations, phenotypic diversity and disease prognosis 








Figure 9. The identified putative phenotype-modifying genetic variants can 
explain the phenotypic differences between PLS and HMS patients carrying 
the same disease-causing CTSC mutation (p.Arg250X). 
 
 
Our finding suggests relevant clinical implications. Although the identification of 
disease-causing mutations remains extremely important for family planning and for 
the development of novel causative therapeutic modalities, it is not always able to 
answer clinically relevant questions about phenotype diversity and disease 
prognosis. According to our view, the next big challenge in human genetics and  
clinical genetics is to identify these variants. We have joined to this new direction 
with these investigations demonstrated in my thesis. We are convinced that in the 
future the results of such investigations will highly contribute to the explanation of 
the phenotypic differences observed in monogenic diseases and contribute to the 
deep exploration of the genotype-phenotype relationships. In the clinical practice - 
primarily in genetic counseling - this knowledge will help us to make a more careful 
and accurate assessment of the prognosis of monogenic diseases. 









My investigations focused on the identification of putative phenotype modifying 
genetic factors in two groups of rare monogenic diseases, which are responsible for 
the observed phenotypic differences among the affected patients carrying the same 
disease-causing CYLD or CTSC mutations. 
We recently investigated a Hungarian and an Anglo-Saxon pedigree affected by 
Brooke-Spiegler syndrome (BSS). Despite carrying the same disease-causing 
mutation (c.2806C>T, p.Arg936X) of the CYLD gene, the affected family members 
of the two pedigrees exhibit striking differences in their phenotypes. To identify 
phenotype-modifying genetic factors, WES was performed and the data from the 
Hungarian and Anglo-Saxon BSS patients were compared. 
Three putative phenotype-modifying genetic variants were identified: the 
rs1053023 SNP of the signal transducer and activator of transcription 3 gene, the 
rs1131877 SNP of the tumor necrosis factor receptor-associated factor 3 gene and 
the rs202122812 SNP of the neighbor of BRCA1 gene 1 gene and the functional 
relevance of the genetic variants were predicted by in silico methods.  
We investigated two Hungarian patients suffering from different phenotypic 
variants (PLS and HMS) but carrying the same homozygous nonsense CTSC 
mutation (c.748C/T; p.Arg250X). To gain insights into phenotype modifying 
associations, WES was performed for both patients and the results were compared 
to identify potentially relevant genetic modifying factors.  
WES revealed two putative phenotype-modifying variants: a missense mutation 
(rs34608771) of the SH2 domain containing 4A (SH2D4A) gene encoding an 
adaptor protein involved in the intracellular signaling of the cystatin F, a known 
inhibitor of the cathepsin protein, and a missense variant (rs55695858) of the 
odorant binding protein 2A (OBP2A) gene influencing the function of the cathepsin 
protein through the glycosyltransferase 6 domain containing 1 (GLT6D1) protein. 
In silico analysis and literature search results explained how the effected proteins 
are linked to CTSC and possibly modify its functions. 
Our investigations contribute to the accumulating evidence on the clinical 
importance of the identification of phenotype-modifying genetic factors. In the 
future it will have high potential in the elucidation of genotype–phenotype 






8. LIST OF ABBREVIATIONS 
 
BCL3 = B-cell CLL/lymphoma 3 
BSS = Brooke-Spiegler syndrome 
CTSC = cathepsin C gene 
CMT = Charcot-Marie-Tooth disease 
CYLD = cylindromatosis gene 
HMS = Haim-Munk syndrome 
HGP = Human Genome Project 
NBR1 = neighbor of BRCA1 gene 1 gene 
NF-κB = nuclear factor‐κB  
PLS = Papillon-Lefèvre syndrome 
SNP = single-nucleotide polymorphism 
SQSTM1 = sequestosome 1 
STAT3 = signal transducer and activator of transcription 3 gene 
TRAF3 = tumor necrosis factor receptor-associated factor 3 gene  
TRAIP = TRAF-interacting protein 
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